Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents.
Antiangiogenic agent
Thyroid malignancy
Tyrosine kinase inhibitors
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Dec 2020
02 Dec 2020
Historique:
received:
03
01
2020
accepted:
26
11
2020
entrez:
3
12
2020
pubmed:
4
12
2020
medline:
13
5
2021
Statut:
epublish
Résumé
Thyroid malignancies are among the most common endocrine cancers worldwide. Owing to the angiogenic nature of these malignancies, tyrosine kinase inhibitors (TKIs) are an attractive potential treatment. However, TKIs have been associated with an increased risk of tumor cavitation, in turn linked to poor outcomes, in patients with malignancies in the lungs, where thyroid cancer commonly metastasizes. We performe d a retrospective cohort study of patients with thyroid cancer and evidence of metastatic disease to the lung that were treated with multi-targeted antiangiogenic TKIs. The primary objective of this study was to determine the incidence of pulmonary cavitation. The secondary objective was to evaluate the effect of pulmonary cavitation on survival. Of the 83 patients with pulmonary nodules, 10 developed cavitation during treatment. Of these 83 patients, two patients had to stop the treatment due to pneumothorax. Additionally, cavitation did not demonstrate any significant effect on survival. In patients with thyroid cancer and evidence of metastatic disease to the chest, the use of multi-targeted TKIs led to cavitations that were not uncommon but clinical consequences were marginal. Treatment was stopped only in two patients that developed pneumothorax, however the small sample is a strong limitation of our study.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid malignancies are among the most common endocrine cancers worldwide. Owing to the angiogenic nature of these malignancies, tyrosine kinase inhibitors (TKIs) are an attractive potential treatment. However, TKIs have been associated with an increased risk of tumor cavitation, in turn linked to poor outcomes, in patients with malignancies in the lungs, where thyroid cancer commonly metastasizes.
METHOD
METHODS
We performe d a retrospective cohort study of patients with thyroid cancer and evidence of metastatic disease to the lung that were treated with multi-targeted antiangiogenic TKIs. The primary objective of this study was to determine the incidence of pulmonary cavitation. The secondary objective was to evaluate the effect of pulmonary cavitation on survival.
RESULTS
RESULTS
Of the 83 patients with pulmonary nodules, 10 developed cavitation during treatment. Of these 83 patients, two patients had to stop the treatment due to pneumothorax. Additionally, cavitation did not demonstrate any significant effect on survival.
CONCLUSION
CONCLUSIONS
In patients with thyroid cancer and evidence of metastatic disease to the chest, the use of multi-targeted TKIs led to cavitations that were not uncommon but clinical consequences were marginal. Treatment was stopped only in two patients that developed pneumothorax, however the small sample is a strong limitation of our study.
Identifiants
pubmed: 33267782
doi: 10.1186/s12885-020-07693-5
pii: 10.1186/s12885-020-07693-5
pmc: PMC7709335
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1181Références
Am J Roentgenol Radium Ther Nucl Med. 1961 Feb;85:277-93
pubmed: 13723326
J Clin Oncol. 2012 Jan 10;30(2):134-41
pubmed: 22025146
Thyroid. 2002 Nov;12(11):953-61
pubmed: 12490072
Ann Thorac Cardiovasc Surg. 1998 Jun;4(3):154-8
pubmed: 9660914
J Clin Oncol. 2013 Oct 10;31(29):3639-46
pubmed: 24002501
Crit Rev Oncol Hematol. 2007 May;62(2):93-104
pubmed: 17306557
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
J Clin Oncol. 2009 Jan 20;27(3):404-10
pubmed: 19047292
Expert Opin Pharmacother. 2016 Aug;17(12):1683-91
pubmed: 27398740
Cancer. 2015 Aug 15;121(16):2749-56
pubmed: 25913680
Thyroid. 2018 Jul;28(7):945-951
pubmed: 29742974
Am Health Drug Benefits. 2015 Feb;8(1):30-40
pubmed: 25964831
Cancer Control. 2006 Apr;13(2):119-28
pubmed: 16735986
J Thorac Oncol. 2008 Apr;3(4):351-7
pubmed: 18379352
Neoplasma. 2003;50(1):66-73
pubmed: 12687281
Int J Mol Sci. 2015 Mar 17;16(3):6153-82
pubmed: 25789503
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Cancer Imaging. 2012 Jun 29;12:225-35
pubmed: 22743083
J Pediatr Surg. 2015 Sep;50(9):1484-9
pubmed: 25783402